HonCode

Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 01-14-2008, 11:36 AM   #1
Cathya
Senior Member
 
Cathya's Avatar
 
Join Date: Sep 2005
Location: Ontario, Canada
Posts: 752
Biomarker may identify ovarian cancer

'Biomarker' may identify ovarian cancer
Guelph university scientists hope to detect early stages of 'silent killer'
Melissa Leong
National Post


CREDIT: Canwest News Service
Scientists at the University of Guelph are in the process of developing a way to test for ovarian cancer using the cancer's biomarkers found in the blood. Ovarian cancer is typically detected in the later stages of the disease, but the new method would allow for a diagnosis to be made sooner.
Scientists at the University of Guelph say they are developing a means of detecting ovarian cancer -- known as the silent killer -- in its early stages, a breakthrough that could save thousands of lives annually.
Dr. Jim Petrik, a biomedical science professor at the university, and his colleagues are creating a "biomarker" to identify the presence of the disease.
"Ovarian cancer has been termed the silent killer because it progresses without any appreciable symptoms until it is at a very advanced stage," Dr. Petrik said. "The really frustrating thing is that ovarian cancer, in its early stages, is a very treatable disease."
In the diseased mice, as well as in humans, a particular protein, Vascular Endothelial Growth Factor (VEGF), is secreted when cancer cells interact with the ovary.
"The protein is secreted in such high amounts that it is detectable in elevated levels in the blood. It potentially will allow us to develop some screening methods to detect the disease earlier," Dr. Petrik said yesterday.
The researchers are assembling a panel of proteins for a screening test because reliable detection may depend on a combination of proteins.
Dr. Barbara Vanderhyden, chairwoman of the research committee at Ovarian Cancer Canada, said the greatest need against the disease is early detection. So far, it has been an elusive goal.
"Potential biomarkers are being tested ... I'm very hopeful that something will be available in five years," said Dr. Vanderhyden, who is a professor in the department of cellular and molecular medicine at the University of Ottawa.
Researchers at the University of Pittsburgh are finalizing their own panels to detect ovarian cancer; the biomarkers perform at about 96% accuracy, said Dr. Anna Lokshin, lead researcher at the university.
Dr. Petrik and the team at the University of Guelph are also working on a possible treatment involving drugs that can cut off the blood supply to the ovarian tumour. The protein, VEGF, stimulates the creation of new blood vessels which help the tumour grow.
"If we can prevent or inhibit expression of VEGF, we can prevent tumour formation from reoccuring and regress established tumours."
The scientists received $500,000 from the Ontario Institute for Cancer Research in 2005 to study ovarian cancer. They are using a unique mouse model which replicates the early stages of human ovarian cancer.
Prior to the new model, researchers used mice with compromised immune systems and infected them by injecting human cancer cells into the rodents' abdomens. But because the mice had immunodeficiencies, it was not a true representation of disease progression in normal animals, Dr. Petrik said.
Researchers at the University of Guelph now inject cancer cells into the thin tissue surrounding the ovary in healthy mice. Their research will be published in a leading cancer journal, Gynecologic Oncology.
It is not easy to diagnose ovarian cancer. The symptoms in the early stages may be vague.
Later, as the tumour enlarges and cancer spreads, it presses against the bowels or other organs causing symptoms such as diarrhea or constipation, pain or swelling of the abdomen, nausea, gas, bloating and leg or back pain.
Ovan cancer affects about one in 70 Canadian women. About 2,300 Canadian women are diagnosed with ovarian cancer each year and 1,600 women die from the disease.
Some studies have indicated that women may reduce their risk of developing ovarian cancer by using oral contraceptives, giving birth to at least one child, breast-feeding and having a hysterectomy or tubal ligation.

© National Post 2008
__________________
Cathy

Diagnosed Oct. 2004 3 cm ductal, lumpectomy Nov. 2004
Diagnosed Jan. 2005 tumor in supraclavicular node
Stage 3c, Grade 3, ER/PR+, Her2++
4 AC, 4 Taxol, Radiation, Arimidex, Actonel
Herceptin for 9 months until Muga dropped and heart enlarged
Restarting herceptin weekly after 4 months off
Stopped herceptin after four weekly treatments....score dropped to 41
Finished 6 years Arimidex
May 2015 diagnosed with ovarian cancer
Stage 1C
started 6 treatments of carboplatin/taxol
Genetic testing show BRCA1 VUS
Nice! My hair came back really curly. Hope it lasts lol. Well it didn't but I liked it so I'm now a perm lady
29 March 2018 Lung biopsy following chest CT showing tumours in pleura of left lung, waiting for results to the question bc or ovarian
April 20, 2018 BC mets confirmed, ER/PR+ now Her2-
Questions about the possibility of ovarian spread and mets to bones so will be tested and monitored for these.
To begin new drug Palbociclib (Ibrance) along with Letrozole May, 2018.
Genetic testing of ovarian tumour and this new lung met will take months.
To see geneticist to be retested for BRCA this week....still BRCA VUS
CA125 has declined from 359 to 12 as of Aug.23/18


Cathya is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump


All times are GMT -7. The time now is 11:35 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter